Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 15;102(6):1797–1806. doi: 10.1210/jc.2016-2855

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article has been published under the terms of the Creative Commons Attribution License (CC BY; https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Copyright for this article is retained by the author(s).

PMC Copyright notice

Figure 5. — Urinary steroid excretion in 60 healthy controls and patients with CAH treated with Chronocort (n = 16), conventional immediate-release hydrocortisone (n = 13), prednisolone (n = 27), or dexamethasone (n = 15). (A) Sum of active androgen metabolites. (B) Signature alternative pathway metabolite. (C) 11β-hydroxyandrosterone, the major metabolite of the 11-oxygenated androgen pathway. (D) Sum of 17OHP metabolites. (E) Glucocorticoid metabolite 11-hydroxy-etiocholanolone. (F) Glucocorticoid metabolite 11-oxo-etiocholanolone. Urinary excretion of 3α5α-17HP available for 54 of the total CAH cohort; 16 on Chronocort, 11 on conventional hydrocortisone, 21 on prednisolone, and 6 on dexamethasone. GC treatment was stable for at least 6 months at the time of 24-hour urine collection. Box-and-whisker plots represent median, interquartile range (box), and 5th and 95th percentiles (whiskers). Analyses were undertaken using the Kruskal-Wallis test with post hoc Dunn. *P ≤ 0.05, ***P ≤ 0.001. PT, pregnanetriol; THS, tetrahydro-11-deoxycortisol.